Skip to content
Sign in

Company

Actinium Pharmaceuticals

Open structure map

Structure of Actinium Pharmaceuticals

Actinium Pharmaceuticals

Company

10 connections
UpstreamSupply and dependency
OwnProducts and technology
DownstreamCustomers
PeersCompetition and partners
ConstraintsRegulation and exposure
Relationship began2026
Actinium PharmaceuticalsCompany · 10 connections
Layer 1

UpstreamSupply and dependency5

DownstreamCustomers1

PeersCompetition and partners1

OwnProducts and technology1

ConstraintsRegulation and exposure2

Place in the network

No. 2180 of 118934top 2%up 5605 places this week

10 direct links

In a group of 451 closely linked entities, around

New links this week

Weighted by public relations with evidence, recomputed daily.

Relations

Arrows show the direction of the relationship. Filter to focus on a business area.

  • Actinium Pharmaceuticalspartners with →National Cancer Institute
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-17 05:00
      Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI)
      View source
    • CompanyPR Newswire news releases2026-10-16 19:30
      Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI)
      View source
    • CompanyPR Newswire news releases2026-10-16 19:30
      with additional development ongoing through a CRADA with the NCI.
      View source
    • CompanyPR Newswire news releases2026-10-15 19:30
      Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI)
      View source
  • Sean Maenpaapart of →Actinium Pharmaceuticals
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-16 19:30
      announced the appointment of Sean Maenpaa as Senior Vice President, Business Development
      View source
  • Actinium Pharmaceuticalsregulatory exposure →Securities and Exchange Commission
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-17 05:00
      risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC")
      View source
  • Actinium Pharmaceuticalsdemand exposure →Actinium's products and services
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-17 05:00
      the market demand for and acceptance of Actinium's products and services
      View source
  • Actinium Pharmaceuticalsuses →HER3
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-17 20:00
      Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400
      View source
  • Actinium Pharmaceuticalsuses →Iomab-ACT
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-17 20:00
      Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.
      View source
  • Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-17 20:00
      Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.
      View source
  • Actinium Pharmaceuticalsuses →Actimab-A
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-17 20:00
      Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.
      View source

Showing 1 to 8 of 10

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 3
regulatory exposureFDA

These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from anticipated or estimated future results, including risks and uncertainties associated with the conduct, timing and r…

PR Newswire news releases · 2026-11-17 20:00

View evidence
  • CompanyPR Newswire news releases2026-11-17 20:00
    These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from anticipated or estimated future results, including risks and uncertainties associated with the conduct, timing and r…
    View source
  • CompanyPR Newswire news releases2026-10-17 05:00
    actions by the FDA and other governmental agencies
    View source
  • CompanyPR Newswire news releases2026-10-16 19:30
    risks and uncertainties associated with the Company's ability to retain key personnel, the Company's ability to identify, negotiate and complete business development, partnering, licensing or other strategic transactions on favorable terms or at all, estimates of potential marke…
    View source
FactEvidence 1

Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.

PR Newswire news releases · 2026-11-17 20:00

View evidence
  • CompanyPR Newswire news releases2026-11-17 20:00
    Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.
    View source
FactEvidence 2

Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400

PR Newswire news releases · 2026-11-17 20:00

View evidence
  • CompanyPR Newswire news releases2026-11-17 20:00
    Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400
    View source
  • CompanyPR Newswire news releases2026-11-17 20:00
    Actinium will present preclinical data demonstrating ATNM-400's activity across therapy-resistant breast cancer models, further supporting its potential across multiple solid tumor indications.
    View source
FactEvidence 1
expected operations funding through2027

Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.

PR Newswire news releases · 2026-11-17 20:00

View evidence
  • CompanyPR Newswire news releases2026-11-17 20:00
    Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.
    View source
FactEvidence 1
cash and cash equivalents28.7 million

Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.

PR Newswire news releases · 2026-11-17 20:00

View evidence
  • CompanyPR Newswire news releases2026-11-17 20:00
    Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.
    View source
FactEvidence 1

Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.

PR Newswire news releases · 2026-11-17 20:00

View evidence
  • CompanyPR Newswire news releases2026-11-17 20:00
    Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.
    View source

Showing 1 to 6 of 18

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Suggest a page to watch

Know a page of this company that matters, such as pricing, a changelog, terms or careers? Suggest it. We read every suggestion; a page we add is watched for everyone, and we only count a change when two looks in a row agree.

Sign in to suggest a page

Not available: Company signals · Financials · Filings · Sites · Guidance